



SUBCUTANEOUS IMMUNOGLOBULIN (SCIG) ADMINISTRATION GUIDE



Not actual size.

PIDD, primary humoral immunodeficiency disease.

Indication

XEMBIFY® (immune globulin subcutaneous human-klhw) is a 20% immune globulin indicated for treatment of primary humoral immunodeficiency disease (PIDD) in patients 2 years of age and older. XEMBIFY is for subcutaneous administration only.

Please see [Important Safety Information](#) on pages 38-39 and refer to full [Prescribing Information](#) for XEMBIFY.

GRIFOLS

TABLE OF CONTENTS

INTRODUCTION

PIDD AT A GLANCE	3
WHAT IS IMMUNE GLOBULIN (IG)?	4
GRIFOLS: A LEADING SOURCE OF IG	6
THE STATE-OF-THE-ART MANUFACTURING PROCESS FOR XEMBIFY	8
THE UNIQUE MANUFACTURING PROCESS FOR XEMBIFY YIELDS ≥ 98% IgG PROTEIN	12
THE DISTINCT PURIFICATION PROCESS YIELDS A MAXIMUM PERCENTAGE OF IgG	13
PRODUCT CHARACTERISTICS TO MEET A WIDE RANGE OF PATIENT NEEDS	14
PROVEN TOLERABILITY ACROSS A WIDE RANGE OF PATIENTS	15
MAXIMUM POTENCY AND PROVEN TOLERABILITY WITH XEMBIFY	16

DOSING

PROVEN TOLERABILITY WITH DOSING FLEXIBILITY THAT MEETS YOUR PATIENTS' NEEDS	18
CHOICE OF VIAL SIZES	20

ROLE OF THE NURSE IN SCIG

FACILITATING SUCCESSFUL SCIG SELF-INFUSIONS	21
FACTORS THAT INFLUENCE THE SUCCESS OF SCIG THERAPY	22
MONITORING PATIENTS UNDERGOING INFUSIONS FOR PIDD	23
INSPECTING XEMBIFY	24
FACTORS TO CONSIDER WHEN SELECTING SITES FOR INFUSIONS	25

ADMINISTRATION OF SCIG

XEMBIFY SCIG INFUSION	26
WHAT TO LOOK FOR DURING SCIG ADMINISTRATION	29

ADVERSE REACTIONS

COMMON ADVERSE REACTIONS WITH SCIG INFUSIONS	30
DOCUMENTING PIDD SCIG INFUSIONS	32

Xembify Connexions™

ACCESS, SUPPORT, AND RESOURCES FOR YOUR PATIENTS	34
XEMBIFY PATIENT STARTER KIT	36

IMPORTANT SAFETY INFORMATION

Please see [Important Safety Information](#)
on pages 38-39 and refer to full
[Prescribing Information](#) for XEMBIFY.



PIDD AT A GLANCE: KNOW THE SIGNS AND SYMPTOMS

Primary immunodeficiency disease is a group of more than 550 immunodeficiency disorders caused by genetic variants that affect the immune system. People with PIDD may be more susceptible to infections, especially those caused by bacteria, viruses, and fungi¹⁻³

Signs and symptoms of PIDD can vary in number and severity for each patient due to the heterogeneous nature of the disease.^{3,4}

Antibody deficiencies are the most common type of PIDD, accounting for more than 50% of disorders.⁵

70% to 90% of people with PIDD worldwide remain undiagnosed³

Time to diagnosis often takes many years. Symptoms are heterogeneous and can complicate the diagnosis.^{3,6}

Patients with undiagnosed PIDD may experience increased morbidity and mortality.⁷

Living with undiagnosed PIDD adversely affects prognosis and increases patient risk for^{7,8}:



**CHRONIC
COMPLICATIONS**



**MORE FREQUENT
AND LONGER
HOSPITAL STAYS**



**PSYCHOSOCIAL
BURDENS**



**REDUCED
QUALITY OF LIFE**

PIDD, primary humoral immunodeficiency disease.

Please see [Important Safety Information](#) on pages 38-39 and refer to full [Prescribing Information](#) for XEMBIFY.

 **Xembify[®]**
(immune globulin subcutaneous
human-klhw) 20%

| WHAT IS IMMUNE GLOBULIN (IG)?

IG is an antibody made by the body's immune system⁹



Plasma is the liquid part of blood that remains after blood cells are removed and it contains many proteins, including antibodies.^{9,10}



Although there are 5 types of antibodies (IgG, IgM, IgD, IgA, and IgE), IG products predominantly contain IgG.^{9,11}

IgA, immunoglobulin A; IgD, immunoglobulin D; IgE, immunoglobulin E; IgG, immunoglobulin G; IgM, immunoglobulin M.

Please see [Important Safety Information](#) on pages 38-39 and refer to full [Prescribing Information](#) for XEMBIFY.

 **Xembify**[®]
(immune globulin subcutaneous
human-klhw) 20%

WHAT IS IMMUNE GLOBULIN (IG)? (cont.)



The IgG antibody is a Y-shaped molecule with antigen-binding sites at the tip of each arm of the Y.⁹



Antibodies protect against infection by coating the microbes and signaling the body to destroy them.⁹



IG is used to treat a spectrum of immune disorders, including PIDD¹²

IgG, immunoglobulin G; PIDD, primary humoral immunodeficiency disease.

Please see [Important Safety Information](#) on pages 38-39 and refer to full [Prescribing Information](#) for XEMBIFY.

 **Xembify**[®]
(immune globulin subcutaneous
human-klhw) 20%

GRIFOLS: A LEADING SOURCE OF IG

Grifols has nearly 300 plasma donation centers across the United States¹³

The plasma donation process at Grifols has several steps, each with rigorous built-in safety measures.¹³



STEP 1: CHECK-IN

Plasma donors check in at the donation center with their identification and proof of address.¹⁴ The National Donor Deferral Registry will be checked to verify donor eligibility.¹⁵



STEP 2: SCREENING

Volunteer donors undergo health screening that includes their medical history, vital signs (weight, blood pressure, pulse, and temperature), and basic chemistries to ensure the health of the donor.¹⁴



STEP 3: PHYSICAL EXAM

Donors go through a physical exam before their first donation and once a year thereafter.¹⁴

IG, immune globulin.

Please see [Important Safety Information](#) on pages 38-39 and refer to full [Prescribing Information](#) for XEMBIFY.

 **Xembify**[®]
(immune globulin subcutaneous
human-klhw) 20%

GRIFOLS: A LEADING SOURCE OF IG (cont.)



STEP 4: PLASMA DONATION

Plasmapheresis is a method of removing plasma from the body by withdrawing blood, separating it into plasma and red blood cells, and returning the red blood cells back into the bloodstream.¹⁴



STEP 5: COMPLETION

Plasma regenerates very quickly, giving volunteers the opportunity to donate twice in a 7-day period with at least 48 hours between donations. Donors are given instructions to take it easy and to drink lots of water.¹⁴



It takes an average of 130 plasma donations to treat 1 patient with PIDD for 1 year¹³

Because XEMBIFY is made from human blood, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.¹⁶

IG, immune globulin; PIDD, primary humoral immunodeficiency disease.

Please see [Important Safety Information](#) on pages 38-39 and refer to full [Prescribing Information](#) for XEMBIFY.

 **Xembify®**
(immune globulin subcutaneous
human-klhw) 20%

THE STATE-OF-THE-ART MANUFACTURING PROCESS FOR XEMBIFY

Grifols manufactures IG using a process that can take 9 to 12 months from donation to finished product¹³



STEP 1: PLASMA DONATION TESTING

- Plasma donations are collected from healthy donors and tested for viral markers.¹³

IG, immune globulin.

Please see [Important Safety Information](#) on pages 38-39 and refer to full [Prescribing Information](#) for XEMBIFY.

 **Xembify**[®]
(immune globulin subcutaneous
human-klhw) 20%

THE STATE-OF-THE-ART MANUFACTURING PROCESS FOR XEMBIFY (cont.)



STEP 2: PLASMA POOLING

- Plasma donations from healthy donors are combined into a fractionation pool.^{13,14}



STEP 3: PLASMA FRACTIONATION

- Pooled plasma is separated into various proteins that will be used to make plasma-derived therapies.^{13,14}
- XEMBIFY is purified from the fraction that has concentrated IgG.¹⁶

IgG, immunoglobulin G.


Please see [Important Safety Information](#) on pages 38-39 and refer to full [Prescribing Information](#) for XEMBIFY.

 **Xembify**[®]
(immune globulin subcutaneous
human-klhw) 20%

THE STATE-OF-THE-ART MANUFACTURING PROCESS FOR XEMBIFY (cont.)

STEP 4: PROTEIN PURIFICATION

- XEMBIFY is purified using a unique caprylate/chromatography process.¹⁶
- During purification, the IgG proteins remain in the solution, minimizing the risk of denaturing the IgG molecules.¹⁷
- The purification process yields a final IgG product that closely reflects the IgG subclass distribution found in normal human plasma.¹⁸
- The process includes protein purification steps with pathogen clearance capacity, including caprylate precipitation/depth filtration, depth filtration, and column chromatography.¹⁶
- In addition, the process includes dedicated steps with pathogen clearance capacity, including caprylate incubation, nanofiltration, and low pH incubation.¹⁶



IgG, immunoglobulin G.

Please see [Important Safety Information](#)
on pages 38-39 and refer to full
[Prescribing Information](#) for XEMBIFY.

 **Xembify**[®]
(immune globulin subcutaneous
human-klhw) 20%

THE STATE-OF-THE-ART MANUFACTURING PROCESS FOR XEMBIFY (cont.)

STEP 5: FORMULATION

- Formulation at low pH provides a stable IgG solution.¹⁷
- XEMBIFY contains glycine as a stabilizer.^{16,18}
- The purified product is then packaged into vials. XEMBIFY is available in multiple vial sizes: 1 g, 2 g, 4 g, and 10 g.¹⁶
- Grifols employs PediGri®—a system that provides complete traceability and easy access to all information about each batch of XEMBIFY, from plasma donation to finished product.¹³



Not actual sizes.



Grifols manufactures IG using a state-of-the-art process focused on safety at every step, from donation to finished product

Because XEMBIFY is made from human blood, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.¹⁶

IG, immune globulin; IgG, immunoglobulin G.

Please see [Important Safety Information](#) on pages 38-39 and refer to full [Prescribing Information](#) for XEMBIFY.

 **Xembify®**
(immune globulin subcutaneous
human-klhw) 20%

THE UNIQUE MANUFACTURING PROCESS FOR XEMBIFY YIELDS $\geq 98\%$ IgG PROTEIN^{16,18}

CAPRYLATE PRECIPITATION AND INCUBATION

- Caprylate is added to a fractionated plasma solution.
- Viruses and impurities are removed while protecting the structure and function of IgG.
- **IgG is maintained in liquid phase to minimize denaturing of the protein.**



ANION-EXCHANGE CHROMATOGRAPHY

- Removes non-IgG proteins
- Removes caprylate
- **Yields maximum percentage ($\geq 98\%$) of IgG and maximum monomeric levels**

IgG, immunoglobulin G.

Please see [Important Safety Information](#) on pages 38-39 and refer to full [Prescribing Information](#) for XEMBIFY.

 **Xembify**[®]
(immune globulin subcutaneous
human-klhw) 20%

THE DISTINCT PURIFICATION PROCESS YIELDS A MAXIMUM PERCENTAGE OF IgG^{16,18}

≥ 98%
IgG

MAXIMUM PURITY^{4,16,18}

- The unique caprylate chromatography process yields a highly purified IG product with ≥ 98% IgG* and proven infection protection.



QUICK AND SUSTAINED STEADY STATE⁴

- Peak IG levels reached in an average of just 3 days
 - Reliable IgG level with an average low of 1263 mg/dL and an average high of 1358 mg/dL achieved at ~3 days with a mean IgG trough level that was 33% higher than IVIG[†]
- IgG concentrations consistently maintained above the commonly accepted therapeutic threshold (500 mg/dL)
- No difference in pharmacokinetic profile among all age groups

Grifols' consistent purification process allows a seamless transition from IVIG to SCIG^{16,18}

XEMBIFY is concentrated into a 20% SCIG through ultrafiltration.

IG, immune globulin; IgA, immunoglobulin A; IgG, immunoglobulin G; IgM, immunoglobulin M; IVIG, intravenous immunoglobulin; SCIG, subcutaneous immunoglobulin.

*The average IgA content is ≤ 0.07 mg/mL and the average IgM content is < 0.004 mg/mL.¹⁸

[†]These levels were achieved with weekly dosing following conversion from IVIG using a dose adjustment factor of 1.37.¹⁶

Please see [Important Safety Information](#) on pages 38-39 and refer to full [Prescribing Information](#) for XEMBIFY.

 **Xembify**[®]
(immune globulin subcutaneous
human-klhw) 20%

PRODUCT CHARACTERISTICS TO MEET A WIDE RANGE OF PATIENT NEEDS^{4,11,16}



SUGAR-FREE¹⁶



**STABILIZED WITH
GLYCINE⁴**



**TRACE AMOUNTS
OF SODIUM¹¹**

XEMBIFY is contraindicated in patients who have had an anaphylactic or severe systemic reaction to the administration of human IG. XEMBIFY is contraindicated in patients who are IgA deficient, have antibodies against IgA, and a history of hypersensitivity.¹⁶

IG, immune globulin; IgA, immunoglobulin A.

Please see [Important Safety Information](#)
on pages 38-39 and refer to full
[Prescribing Information](#) for XEMBIFY.

 **Xembify[®]**
(immune globulin subcutaneous
human-klhw) 20%

PROVEN TOLERABILITY ACROSS A WIDE RANGE OF PATIENTS^{4,16}

Observed in a multicenter, open-label, phase 3 study^{4,16}



0 DRUG-RELATED SERIOUS ADVERSE EVENTS



0 SERIOUS OR SEVERE INFUSION-SITE REACTIONS



< 0.001 HEADACHES PER INFUSION



0 REPORTS OF NAUSEA OR FATIGUE

NO NOTICEABLE TOLERABILITY DIFFERENCES WERE OBSERVED ACROSS AGE GROUPS⁴

- All but one adverse event were mild or moderate.*
- Results per subject: overall rate of headaches (1/49); overall rate of systemic adverse reactions (7/49)

SC, subcutaneous.

*One subject, who experienced a severe potentially related adverse event during the SC phase (on day 20), had polymyalgia rheumatica, which was considered unlikely related to the study drug and resolved by day 75.⁴


Please see [Important Safety Information](#)
on pages 38-39 and refer to full
[Prescribing Information](#) for XEMBIFY.

 **Xembify**[®]
(immune globulin subcutaneous
human-klhw) 20%

MAXIMUM POTENCY AND PROVEN TOLERABILITY WITH XEMBIFY^{4,16}

> 50% fewer infusion-site reactions by week 24⁴

Percentage of subjects reporting infusion-site reactions



Results from an open-label, multicenter, phase 3 clinical study of patients with primary immunodeficiency (N=49).⁴

Local infusion-site reactions decreased from ~34% to ~14%, from the start to the end of the 24-week SC phase, reflecting a > 50% reduction.⁴

SC, subcutaneous.

Please see [Important Safety Information](#) on pages 38-39 and refer to full [Prescribing Information](#) for XEMBIFY.



MAXIMUM POTENCY AND PROVEN TOLERABILITY WITH XEMBIFY (cont.)^{4,16}

Adverse reactions in $\geq 5\%$ of subjects^{4,16}

Adverse Reactions*	By Subject n (%) (N=49)	By Infusion n (rate) [†] (N=1053)
Local adverse reactions		
Infusion-site erythema	19 (39)	123 (0.117)
Infusion-site pain	9 (18)	32 (0.030)
Infusion-site swelling	8 (16)	124 (0.118)
Infusion-site bruising	8 (16)	26 (0.025)
Infusion-site nodule	8 (16)	13 (0.012)
Infusion-site pruritus	5 (10)	28 (0.027)
Infusion-site induration	4 (8)	6 (0.006)
Infusion-site scab	3 (6)	6 (0.006)
Infusion-site edema	3 (6)	5 (0.005)
Systemic adverse reactions		
Cough	3 (6)	4 (0.004)
Diarrhea	3 (6)	3 (0.003)

*Including all adverse reactions that occurred after the first dose of XEMBIFY regardless of causality, excluding infections.¹⁶

[†]Rate per infusion is calculated as the total number of adverse reactions divided by the total number of infusions.¹⁶

Please see [Important Safety Information](#)
on pages 38-39 and refer to full
[Prescribing Information](#) for XEMBIFY.



PROVEN TOLERABILITY WITH DOSING FLEXIBILITY THAT MEETS YOUR PATIENTS' NEEDS¹⁶

From first line to treatment experienced, XEMBIFY meets the needs of your patients with PIDD¹⁶

Treatment-Naïve		Switch From IVIG		Switch From SCIG	
Loading Doses (Days 1-5)	150 mg/kg/day for 5 consecutive days	Weekly Dosing*	Initial weekly dose of XEMBIFY in grams=prior IVIG in grams/ number of weeks between IVIG doses x 1.37	Weekly Dosing*	Administer the same weekly dose of XEMBIFY (grams) as the weekly dose of prior SCIG treatment (grams)
Maintenance Dosing (Days 8 and beyond)	Weekly administration of 150 mg/kg/ week starting on day 8 Monitor IgG trough levels every 2 weeks during first 8 weeks	Every-2-Week Dosing	Multiply weekly dose by 2	Every-2-Week Dosing	Multiply weekly dose by 2
Individualize the dose of XEMBIFY based upon each patient's pharmacokinetic and clinical response.					

*XEMBIFY can be administered at regular intervals from daily to up to 2 weeks.¹⁶



For patients switching from a weekly to every-2-weeks dose, multiply the weekly dose by 2¹⁶

- Children may require less total volume for a specific XEMBIFY dose (mg/kg body weight) than adults.
- Children 2 to < 10 years of age have a maximum infusion rate of 25 mL/hr/infusion site.
- The healthcare provider may choose a smaller volume/site for children and/or fewer infusion sites to achieve the target total dose, depending on the needs of the child.

IVIG, intravenous immunoglobulin;
PIDD, primary humoral immunodeficiency disease;
SCIG, subcutaneous immunoglobulin.

Please see [Important Safety Information](#) on pages 38-39 and refer to full [Prescribing Information](#) for XEMBIFY.

 **Xembify®**
(immune globulin subcutaneous human-klhw) 20%

PROVEN TOLERABILITY WITH DOSING FLEXIBILITY THAT MEETS YOUR PATIENTS' NEEDS (cont.)¹⁶

Customizable dosing to meet your
patients' individual needs¹⁶



EVERY 2 WEEKS

to more frequent dosing (1 to 7 times/week)

- SCIG from the start for treatment-naïve patients
- Seamless switch from IVIG or another SCIG
- Infusion rates up to 35 mL/hr/site in patients ≥ 10 years old
- No titration required
- Up to every-2-week dosing
- Up to 6 infusion sites



Scan to calculate the starting dose of XEMBIFY, or
visit: www.xembify.com/en/hcp/dosing-administration

IVIG, intravenous immunoglobulin; SCIG, subcutaneous immunoglobulin.

Please see [Important Safety Information](#)
on pages 38-39 and refer to full
[Prescribing Information](#) for XEMBIFY.

 **Xembify**[®]
(immune globulin subcutaneous
human-klhw) 20%

CHOICE OF VIAL SIZES

XEMBIFY is available in a wide range of vial sizes¹⁶



Not actual sizes.

Convenient handling and storage^{13,16}:

- No refrigeration needed for up to 6 months^{16*}
- Can be stored under refrigeration for up to 36 months^{13*}

*XEMBIFY may be stored for 36 months at 2 to 8 °C (36 to 46 °F) from the date of manufacture and the product may be stored at temperatures not to exceed 25 °C (77 °F) for up to 6 months any time prior to the expiration date. Following 25 °C (77 °F) storage, use the product immediately or discard. Do not freeze.¹⁶

Please see [Important Safety Information](#)
on pages 38-39 and refer to full
[Prescribing Information](#) for XEMBIFY.

 **Xembify®**
(immune globulin subcutaneous
human-klhw) 20%

FACILITATING SUCCESSFUL SCIG SELF-INFUSIONS

Facilitating self-infusions through education¹⁹



Educate patients and caregivers on how to perform SCIG infusions and answer any questions they may have



Teach self-infusion in a systematic, stepwise manner



Follow up with patients regarding any issues with self-infusions



Adjust the infusion process as necessary by changing:

- Needle gauge or length
- Location or number of infusion sites
- Infusion tubing

SCIG, subcutaneous immunoglobulin.

Please see [Important Safety Information](#) on pages 38-39 and refer to full [Prescribing Information](#) for XEMBIFY.

 **Xembify**[®]
(immune globulin subcutaneous
human-klhw) 20%

FACTORS THAT INFLUENCE THE SUCCESS OF SCIG THERAPY

Managing the following factors can help ensure patient success¹⁹:



Efficacy and IgG trough levels

- Dose
- Infusion interval



Tolerability

- Side effect management
- Infusion rate, sites, and volume
- Patient comorbidities
- Product characteristics
- Infusion equipment and technique



Compliance

- Site of care
- Route of administration
- Patient understanding and commitment to therapy

IgG, immunoglobulin G; SCIG, subcutaneous immunoglobulin.

Please see [Important Safety Information](#) on pages 38-39 and refer to full [Prescribing Information](#) for XEMBIFY.

 **Xembify**[®]
(immune globulin subcutaneous
human-klhw) 20%

MONITORING PATIENTS UNDERGOING INFUSIONS FOR PIDD

Some questions you could ask patients or caregivers¹⁹:



How is your IG treatment going so far?



Have you experienced a recent cold, flu, or any symptoms of infection (eg, fever, chills)?



Have you missed any infusions?



Have you been sick or missed any work or school due to illness?



Do you experience fatigue after your infusions?



Is there anything you want to change about your treatment plan?


IG, immune globulin; PIDD, primary humoral immunodeficiency disease.

Please see [Important Safety Information](#) on pages 38-39 and refer to full [Prescribing Information](#) for XEMBIFY.

 **Xembify**[®]
(immune globulin subcutaneous
human-klhw) 20%

INSPECTING XEMBIFY

Before infusion, check the product for the following^{16,20}:



NEVER SHAKE IG PRODUCT

IG, immune globulin.


Please see [Important Safety Information](#) on pages 38-39 and refer to full [Prescribing Information](#) for XEMBIFY.

 **Xembify®**
(immune globulin subcutaneous human-klhw) 20%

FACTORS TO CONSIDER WHEN SELECTING SITES FOR INFUSIONS

Site selection for adult and pediatric patients
2 years of age and older^{16,20}

- Select areas with adequate subcutaneous tissue.²⁰
- Ensure sites are at least 2 inches apart.¹⁶
- Rotate sites.¹⁶
- Up to 6 sites can be used simultaneously.¹⁶




Green indicates areas for possible infusion sites.¹⁶

Please see [Important Safety Information](#)
on pages 38-39 and refer to full
[Prescribing Information](#) for XEMBIFY.

 **Xembify**[®]
(immune globulin subcutaneous
human-klhw) 20%

XEMBIFY SCIG INFUSION

Consider these steps for preparation of the site and administration



STEP 1

Disinfect surface to be used for the infusion. Allow the vial(s) of XEMBIFY to reach room temperature. Set up all the supplies you will need. Wash and dry your hands thoroughly.¹⁶




STEP 2

Check the vial of XEMBIFY. Confirm the name and expiration date. If the product is past the expiration date, if the liquid is cloudy or has particles, or if the vial shows any sign of tampering, do not use that vial. Tell your healthcare provider immediately.¹⁶



STEP 3

Remove the tamper-resistant seal and protective cap from the vial of XEMBIFY. Clean the rubber stopper with an alcohol wipe and allow to air dry.¹⁶



STEP 4


Draw XEMBIFY into the syringe using either a needle or a transfer device. If you are using a needle, refer to Step 5. If using a transfer device, refer to Step 6.^{16,21}

SCIG, subcutaneous immunoglobulin.

Please see [Important Safety Information](#) on pages 38-39 and refer to full [Prescribing Information](#) for XEMBIFY.


 **Xembify**[®]
(immune globulin subcutaneous
human-klhw) 20%

XEMBIFY SCIG INFUSION (cont.)




STEP 5

Attach the needle to the syringe tip and remove the cap. Pull the syringe plunger back to the level of XEMBIFY you want to withdraw. Place the vial on a flat surface, insert the needle, and inject air. Turn the vial and syringe upside down. Make sure the needle is placed below the fluid level and withdraw XEMBIFY. If using a needle in Step 5, skip to Step 7.¹⁶




STEP 6

Uncap the transfer device and attach it to the syringe. Place the vial on a flat surface and insert the device into the top of the vial. Turn the vial and syringe upside down and withdraw the desired amount of XEMBIFY. Then remove the syringe and transfer device.²¹



STEP 7

Follow the pump manufacturer's instructions to attach the infusion tubing and needle set to the syringe. Be sure to prime the administration tubing by filling it with XEMBIFY. Make sure the needle remains dry while priming.^{16,20}



STEP 8

XEMBIFY may be infused in the abdomen, thigh, upper arm, sides, back, or hip. Select one or more infusion sites as directed by your healthcare provider. Be sure to choose sites that are different from your last infusion.^{16,21}

SCIG, subcutaneous immunoglobulin.

Please see [Important Safety Information](#) on pages 38-39 and refer to full [Prescribing Information](#) for XEMBIFY.


 **Xembify**[®]
(immune globulin subcutaneous
human-klhw) 20%

XEMBIFY SCIG INFUSION (cont.)




STEP 9

Prepare the infusion site(s) by cleaning with an alcohol wipe. The sites should be clean, dry, at least 2 inches apart, and 2 inches away from the belly button. Do not use more than 6 infusion sites at the same time.^{16,20}




STEP 10

Grasp the skin between 2 fingers and insert the needle into the subcutaneous tissue (tissue underneath the skin).¹⁶



STEP 11

Make sure a blood vessel has not been entered. If you see blood when pulling back on the plunger, remove and discard the needle and tubing. Repeat Steps 8 to 10 using a new needle, administration tubing, and infusion site. Secure needle with adhesive dressing. Repeat for other sites as needed.¹⁶



STEP 12

Follow the pump manufacturer's instructions to load the syringe and start the infusion. The infusion is complete when the syringe is empty. Use XEMBIFY within 2 hours of drawing up in a syringe to avoid the potential formation of particles caused by siliconized syringes.^{16,20}

To watch a video on how to administer XEMBIFY, visit:
www.xembify.com/en/hcp/dosing-administration

SCIG, subcutaneous immunoglobulin.

Please see **Important Safety Information** on pages 38-39 and refer to full **Prescribing Information** for XEMBIFY.

 **Xembify**[®]
(immune globulin subcutaneous
human-k(hw) 20%)

WHAT TO LOOK FOR DURING SCIG ADMINISTRATION

Check infusion sites for local adverse reactions such as erythema, discomfort, and swelling²⁰

Troubleshooting infusion-site reactions

- Make sure your patient is following appropriate dry needle-insertion technique.²²
- Consider changing needle length if there is pain or leakage at the infusion site.²¹
- Make sure infusion sites are 2 inches apart and 2 inches from belly button.²⁰
- Make sure patient is rotating sites.²²
- Monitor the amount of fluid per site.¹⁶

Mild infusion-site reaction



Moderate infusion-site reaction




SCIG, subcutaneous immunoglobulin.

Please see [Important Safety Information](#) on pages 38-39 and refer to full [Prescribing Information](#) for XEMBIFY.

 **Xembify**[®]
(immune globulin subcutaneous
human-klhw) 20%

COMMON ADVERSE REACTIONS WITH SCIG INFUSIONS

Local infusion-site reactions are most common^{20,22}



Local itching

POTENTIAL INTERVENTION

- Apply cold compress wrapped in cloth or washcloth to site of itching. Do not apply ice directly to skin.

CONSIDERATIONS FOR FUTURE INFUSIONS

- Use longer needle.
- Decrease volume per site.
- Decrease volume per site and gradually increase to maximum volume.
- Ensure dry needle insertion.
- Apply topical steroid.



Redness

POTENTIAL INTERVENTION

- Apply cold compress. Do not apply directly to skin.

CONSIDERATIONS FOR FUTURE INFUSIONS

- Consider changing dressing tape.
- Inform patient that redness should decrease with each subsequent infusion.

SCIG, subcutaneous immunoglobulin.

Please see [Important Safety Information](#) on pages 38-39 and refer to full [Prescribing Information](#) for XEMBIFY.

 **Xembify**[®]
(immune globulin subcutaneous
human-klhw) 20%

COMMON ADVERSE REACTIONS WITH SCIG INFUSIONS (cont.)²²




Burning

POTENTIAL INTERVENTION

- Clamp catheter for 5 to 10 minutes.
- Apply cold compress. Do not apply directly to skin.
- Remove needle and place in another site.
- Slow rate of infusion.

CONSIDERATIONS FOR FUTURE INFUSIONS

- Decrease infusion rate.
- Consider changing infusion volume.
- Consider shorter needle.
- Consider changing antiseptic used for skin preparation.



Swelling

POTENTIAL INTERVENTION

- Apply warm compress for 5 to 10 minutes (if using a heating pad, use low setting).
- Try gentle massage.

CONSIDERATIONS FOR FUTURE INFUSIONS

- Adjust volume or consider alternate site.



Rash/hives

POTENTIAL INTERVENTION

- Stop infusion and contact prescriber for instructions.

CONSIDERATIONS FOR FUTURE INFUSIONS

- Stop infusion and contact prescriber for instructions.

SCIG, subcutaneous immunoglobulin.

Please see [Important Safety Information](#) on pages 38-39 and refer to full [Prescribing Information](#) for XEMBIFY.

 **Xembify[®]**
(immune globulin subcutaneous
human-klhw) 20%

DOCUMENTING PIDD SCIG INFUSIONS

Encourage your patients to use the XEMBIFY Infusion Log Book to record important information about their infusions²²



Week _____


Notes on my therapy

1 Date of infusion: ____/____/____ Dose infused: ____
mm/dd/yyyy Check one: ☐ grams (g) ☐ milliliters (mL)

Time infusion started: _____ Time infusion ended: _____

Needle size: _____ Infusion rate: _____

3



Number of sites and areas infused this week (please mark with an X).

5

Peel "lot number and expiration date" label from XEMBIFY vial and affix here.

Lot # _____ Expiration date _____

Peel "lot number and expiration date" label from XEMBIFY vial and affix here.

Lot # _____ Expiration date _____

Peel "lot number and expiration date" label from XEMBIFY vial and affix here.

Lot # _____ Expiration date _____

Notes on my therapy

2

Medications I have taken:

BEFORE infusion	DURING infusion	AFTER infusion
_____	_____	_____
_____	_____	_____
_____	_____	_____

4 Side effects I experienced:
Infusion site reactions such as redness, swelling, pain, or itching. Note the time they began and any measures you took to address them.

Overall reactions such as headache, flu-like symptoms, fatigue, fever, and pain or discomfort. Note the time they began and any measures you took to address them.

Questions for my doctor or nurse:

PIDD, primary humoral immunodeficiency disease; SCIG, subcutaneous immunoglobulin.

Please see [Important Safety Information](#) on pages 38-39 and refer to full [Prescribing Information](#) for XEMBIFY.



DOCUMENTING PIDD SCIG INFUSIONS (cont.)

REQUEST THAT YOUR PATIENTS RECORD THE
FOLLOWING INFORMATION^{16,22}:

- 1 Date and time the infusion started and ended
- 2 Exact dose that was infused
- 3 Number and location of infusion sites
- 4 Any side effects they experienced
- 5 Affix the peel-off label from the vial to the allocated space in the log book.

To order more log books for your patients, visit:
www.xembify.com/en/patients/resources-and-information

PIDD, primary humoral immunodeficiency disease; SCIG, subcutaneous immunoglobulin.

Please see [Important Safety Information](#)
on pages 38-39 and refer to full
[Prescribing Information](#) for XEMBIFY.



ACCESS, SUPPORT, AND RESOURCES FOR YOUR PATIENTS



Xembify Connexions™ COPAY PROGRAM*

- \$0 copay for eligible patients
- Up to \$10,000 copay assistance per calendar year, which covers deductibles, copayments, and coinsurance medication cost for XEMBIFY
- No monthly caps or infusion limits
- Patients should complete authorization form.



ACCESS & REIMBURSEMENT SUPPORT

- Coverage criteria, coding, and billing assistance
- Prescription triage to in-network specialty pharmacy
- Copay reimbursement coordination



XEMBIFY PATIENT STARTER KIT

- A free XEMBIFY Patient Starter Kit is available for adult and pediatric patients.
- Once a patient is enrolled, a Xembify Connexions case manager will coordinate with the specialty pharmacy or ship directly to the patient.

*Subject to terms and conditions of the Xembify Connexions copay program. Visit XEMBIFY.com to read the full terms and conditions. Grifols reserves the right to rescind, revoke, or amend the program at any time without notice.

Please see [Important Safety Information](#) on pages 38-39 and refer to full [Prescribing Information](#) for XEMBIFY.



ACCESS, SUPPORT, AND RESOURCES FOR YOUR PATIENTS (cont.)



PATIENT ASSISTANCE PROGRAM (PAP)

- Financial assistance is available for eligible, uninsured patients.
- Speak with a Xembify Connexions Case Manager for application support.
- PAP application form is required.



**Xembify
connexions™**

Xembify Connexions is a support program to provide financial and logistical assistance to ensure a smooth experience with XEMBIFY for both patients and healthcare providers.

**Our case managers are available
Monday through Friday, 8 AM to 8 PM ET.**

**Call 1-844-MYXEMBIFY (1-844-699-3624) or
fax 1-877-375-0758.**



Scan to sign up your patient for Xembify Connexions and receive a free Patient Starter Kit, or visit:
www.xembify.com/en/patients/resources-and-information

Please see **Important Safety Information**
on pages 38-39 and refer to full
Prescribing Information for XEMBIFY.

 **Xembify®**
(immune globulin subcutaneous
human-klhw) 20%

XEMBIFY PATIENT STARTER KIT




Buzzy Bee comfort item


Please see [Important Safety Information](#) on pages 38-39 and refer to full [Prescribing Information](#) for XEMBIFY.

 **Xembify**[®]
(immune globulin subcutaneous
human-klhw) 20%

XEMBIFY PATIENT STARTER KIT (cont.)



Infusion Log Book



Quick Reference Guide

Please see [Important Safety Information](#) on pages 38-39 and refer to full [Prescribing Information](#) for XEMBIFY.



IMPORTANT SAFETY INFORMATION

Indication

XEMBIFY® (immune globulin subcutaneous human-klhw) is a 20% immune globulin indicated for treatment of primary humoral immunodeficiency disease (PID) in patients 2 years of age and older. XEMBIFY is for subcutaneous administration only.

Important Safety Information

WARNING: THROMBOSIS

- **Thrombosis may occur with immune globulin products, including XEMBIFY. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors**
- **For patients at risk of thrombosis, administer XEMBIFY at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity**

Contraindications

XEMBIFY is contraindicated in patients who have had an anaphylactic or severe systemic reaction to the administration of human immune globulin. It is contraindicated in IgA-deficient patients with antibodies against IgA and a history of hypersensitivity.

Warnings and Precautions

Aseptic meningitis syndrome (AMS). AMS may occur with human immune globulin treatment, including XEMBIFY. Conduct a thorough neurological exam on patients exhibiting signs and symptoms to rule out other causes of meningitis. Discontinuation of treatment has resulted in remission within several days without sequelae.

Thrombosis. Thrombosis may occur following treatment with immune globulin products, including XEMBIFY. Thrombosis may occur in the absence of known risk factors. In patients at risk, administer at the minimum dose and infusion rate practicable. Ensure adequate hydration before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.

Hypersensitivity. Severe hypersensitivity reactions may occur with immune globulin products, including XEMBIFY. In case of hypersensitivity, discontinue infusion immediately and institute appropriate treatment. XEMBIFY contains IgA. Patients with known antibodies to IgA may have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions.

Please refer to full **Prescribing Information** for XEMBIFY.



IMPORTANT SAFETY INFORMATION (cont.)

Renal dysfunction/failure. Acute renal dysfunction/failure, acute tubular necrosis, proximal tubular nephropathy, osmotic nephrosis, and death may occur with use of human immune globulin products, especially those containing sucrose. XEMBIFY does not contain sucrose. Ensure patients are not volume-depleted prior to starting infusion. In patients at risk due to preexisting renal insufficiency or predisposition to acute renal failure, assess renal function prior to the initial infusion of XEMBIFY and again at appropriate intervals thereafter. If renal function deteriorates, consider discontinuation.

Hemolysis. XEMBIFY may contain blood group antibodies that may cause a positive direct antiglobulin reaction and hemolysis. Monitor patients for clinical signs and symptoms of hemolysis. If signs and symptoms are present after infusion, perform confirmatory lab testing.

Transfusion-related acute lung injury (TRALI). Noncardiogenic pulmonary edema may occur in patients following treatment with immune globulin products, including XEMBIFY. Monitor patients for pulmonary adverse reactions. If TRALI is suspected, perform appropriate tests for the presence of antineutrophil and anti-HLA antibodies in both the product and patient serum. TRALI may be managed using oxygen therapy with adequate ventilatory support.

Transmissible infectious agents. Because XEMBIFY is made from human blood, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. No cases of transmission of viral diseases, vCJD, or CJD have ever been associated with the use of XEMBIFY.

Interference with lab tests. After infusion of XEMBIFY, passively transferred antibodies in the patient's blood may yield positive serological testing results, with the potential for misleading interpretation.

Adverse Reactions

The most common adverse reactions in $\geq 5\%$ of subjects in the clinical trial were local adverse reactions, including infusion-site erythema (redness), infusion-site pain, infusion-site swelling (puffiness), infusion-site bruising, infusion-site nodule, infusion-site pruritus (itching), infusion-site induration (firmness), infusion-site scab, infusion-site edema, and systemic reactions including cough and diarrhea.

Drug Interactions

Passive transfer of antibodies may transiently interfere with the immune responses to live attenuated virus vaccines (eg, measles, mumps, rubella, and varicella).

Please refer to full **Prescribing Information** for XEMBIFY.





Contact your local IG Nurse Educator
for training on XEMBIFY administration
or your Grifols sales representative for
more information about XEMBIFY therapy.

1-844-MYXEMBIFY
(1-844-699-3624)

XEMBIFY.com

IG, immune globulin.

References: 1. Poli MC, Aksentijevich I, Bousfiha AA, et al. Human inborn errors of immunity: 2024 update on the classification from the International Union of Immunological Societies Expert Committee. *J Hum Immun.* 2025;1(1):e20250003. 2. Immune Deficiency Foundation. About primary immunodeficiency. Immune Deficiency Foundation website. Accessed July 8, 2026. <https://primaryimmune.org/understanding-primary-immunodeficiency/what-is-pi> 3. Meyts I, Bousfiha A, Duff C, et al. Primary immunodeficiencies: a decade of progress and a promising future. *Front Immunol.* 2021;11:625753. 4. Sleasman JW, Lumry WR, Hussain I, et al. Immune globulin subcutaneous, human – klhw 20% for primary humoral immunodeficiency: an open-label, phase III study. *Immunotherapy.* 2019;11(16):1371-1386. 5. Ballou M, Epland K, Heimall J, et al. *Immune Deficiency Foundation Patient & Family Handbook for Primary Immunodeficiency Diseases.* 6th ed. Immune Deficiency Foundation; 2019. 6. Immune Deficiency Foundation. *IDF 2023 National Patient Survey.* 6th ed. Immune Deficiency Foundation; 2023. 7. Anderson JT, Cowan J, Condino-Neto A, Levy D, Prusty S. Health-related quality of life in primary immunodeficiencies: impact of delayed diagnosis and treatment burden. *Clin Immunol.* 2022;236:108931. 8. Rider NL, Kutac C, Hajjar J, et al. Health-related quality of life in adult patients with common variable immunodeficiency disorders and impact of treatment. *J Clin Immunol.* 2017;37(5):461-475. 9. National Institute of Allergy and Infectious Diseases, National Cancer Institute. Understanding the immune system: how it works. US Department of Health and Human Services, National Institutes of Health; 2003. 10. Mathew J, Sankar P, Varacallo MA. Physiology, blood plasma. In: *StatPearls.* StatPearls Publishing; 2026. Updated April 24, 2023. Accessed June 24, 2026. <http://www.ncbi.nlm.nih.gov/books/NBK531504/> 11. Siegel J. Immune globulins: therapeutic, pharmaceutical, cost, and administration considerations. *Pharmacy Practice News.* June 26, 2025. Accessed July 8, 2026. <https://www.pharmacypracticenews.com/Monographs-and-Whitepapers/Article/07-25/Immune-Globulins-Therapeutic-Pharmaceutical-Cost-and-Administration-Considerations/77551> 12. Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: a review of evidence. *J Allergy Clin Immunol.* 2017;139(suppl 3):S1-S46. 13. Data on file, Grifols. 14. Giving=Living. The process for giving plasma, step-by-step. US Department of Health and Human Services website. September 27, 2022. Accessed June 25, 2026. <https://www.hhs.gov/givingequalsliving/giveplasma/giving-process> 15. Plasma Protein Therapeutics Association. Donate plasma. Plasma Protein Therapeutics Association website. Accessed July 8, 2026. <https://www.pptaglobal.org/donate#donation-process> 16. XEMBIFY Prescribing Information. Grifols. July, 2024. 17. Lebing W, Remington KM, Schreiner C, Paul HI. Properties of a new intravenous immunoglobulin (IGIV-C, 10%) produced by virus inactivation with caprylate and column chromatography. *Vox Sang.* 2003;84(3):193-201. 18. Alonso W, Vandeberg P, Lang J, et al. Immune globulin subcutaneous, human 20% solution (Xembify®), a new high concentration immunoglobulin product for subcutaneous administration. *Biologicals.* 2020;64:34-40. 19. Jolles S, Orange J, Gardulf A, et al. Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease. *Clin Exp Immunol.* 2015;179(2):146-160. 20. Immunoglobulin National Society. *Immunoglobulin Therapy: Standards of Practice.* 3.2 ed. Ig Society, Inc.; 2024. 21. Alberta Health Services. *Home Infusion of Subcutaneous Immune Globulin (SCIG).* 22. Immune Deficiency Foundation. *IDF Guide for Nurses: Immunoglobulin Therapy for Primary Immunodeficiency Diseases.* 4th ed. Immune Deficiency Foundation; 2016.